Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 12
2003 13
2004 13
2005 24
2006 30
2007 28
2008 27
2009 18
2010 23
2011 30
2012 31
2013 32
2014 29
2015 44
2016 41
2017 43
2018 46
2019 43
2020 50
2021 81
2022 49
2023 8
Text availability
Article attribute
Article type
Publication date

Search Results

636 results
Results by year
Filters applied: . Clear all
Page 1
Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy.
Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, Graziano RF, Coleman B, Menard K, Yan J, Michaud E, Chang H, Abdel-Hafiz HA, Rozhok AI, Duex JE, Agarwal N, Chauca-Diaz A, Johnson LK, Ng TL, Cambier JC, Clambey ET, Costello JC, Korman AJ, Theodorescu D. Tu MM, et al. Among authors: chang h. Sci Adv. 2019 Feb 20;5(2):eaav2437. doi: 10.1126/sciadv.aav2437. eCollection 2019 Feb. Sci Adv. 2019. PMID: 30801016 Free PMC article.
Assessment of hyperprogression versus the natural course of disease development with nivolumab with or without ipilimumab versus placebo in phase III, randomized, controlled trials.
Kang YK, Reck M, Nghiem P, Feng Y, Plautz G, Kim HR, Owonikoko TK, Boku N, Chen LT, Lei M, Chang H, Lin WH, Roy A, Bello A, Sheng J. Kang YK, et al. Among authors: chang h. J Immunother Cancer. 2022 Apr;10(4):e004273. doi: 10.1136/jitc-2021-004273. J Immunother Cancer. 2022. PMID: 35383114 Free PMC article. Clinical Trial.
636 results